Displaying 161 - 180 of 853
| Active Ingredient | HYDROXYUREA |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Chronic myeloid leukemia. |
| Caution |
Anorexia, nausea and vomiting, stomatitis, leukopenia, thrombocytopenia and anaemia-less marked than leukopenia, megaloblastosis, alopecia is rare. Directly inhibits DNA synthesis primari More ... |
| Dose Range | 20-30mg/kg/day administered as a single dose. |
| Drug Interactions | |
| Pregnancy | Hydroxyurea can cause fetal toxicity when administered to pregnant women, but po More ... |
| Breast Feeding | Hydroxyurea is distributed into milk. Breastfeeding is not recommended during hy More ... |
| Active Ingredient | IMATINIB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Chronic myeloid leukaemia, gastrointestinal stromal tumours . |
| Caution | Abdominal pain; appetite changes; arthralgia; ascites; conjunctivitis; constip ation; cough. |
| Dose Range | 400mg -600mg once a day .Maximum 800mg daily in divided doses. Take with food and plenty of water. |
| Drug Interactions | |
| Pregnancy | Use with caution during pregnancy. Adequate contraception is indicated. |
| Breast Feeding | Not recommended as Imatinib is excreted in breastmilk. |
| Active Ingredient | INFLIXIMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LETROZOLE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Advanced or locally advanced breast cancer in post menopausal women; adjuvant treatment of hormone-receptor-positive early breast cancer in post menopausal women; early invasive cancer in post menopa More ... |
| Caution | Hot flushes, nauear, vomiting, bone fractures, hypercholesterolemia. |
| Dose Range | 2.5mg daily . |
| Drug Interactions | |
| Pregnancy | Letrozole is contraindicated in women who are or may become pregnant (i.e., prem More ... |
| Breast Feeding | Not recommended during letrozole therapy. |
| Active Ingredient | LEUPROLIDE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MEGESTROL |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MELPHALAN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Breast cancer, multiple myeloma |
| Caution |
Anorexia, nausea and vomiting, leukopenia, thrombocytopenia and anaemia. Severe bone marrow suppression with resulting infection or bleeding may occur. |
| Dose Range | Breast Cancer: 150mcg/kg daily in divided doses for 5 days repeated every 6 weeks. Multiple Myeloma: 6mg daily for 2-3 weeks with with rest periods of up to 6 weeks. |
| Drug Interactions | |
| Pregnancy | Therapy may suppress ovarian function and result in amenorrhea |
| Breast Feeding | Not recommended during therapy. |
| Active Ingredient | MERCAPTOPURINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Acute Lymphocytic Leukemia |
| Caution | Nausea, vomiting and anorexia, leukopenia, thrombocytopenia. An antimetabolite. C.f. prescribing in renal disease p. 32. |
| Dose Range | 2.5mg/kg/day or 50-70mg/m2 daily adjusted according to response and tolerance. Maintainence: 1.5-2.5mg/kg/day . |
| Drug Interactions | |
| Pregnancy | Mercaptopurine should only be used during pregnancy when there are no alternativ More ... |
| Breast Feeding | Mercaptopurine is distributed in breastmilk. Breastfeeding is not recommended du More ... |
| Active Ingredient | METHOTREXATE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Rheumatoid arthritis, acute lymphoblastic leukaemia. |
| Caution | Stomatitis, diarrhoea, hepatic dysfunction, thrombocy top enia, bone marrow suppression. Pulmonary toxicity in rheumatoid arthritis (patient to contact doctor immediately if dyspnoea or cough occ More ... |
| Dose Range | Rheumatoid Arthritis: 7.5mg once weekly or 2.5mg every 12 hours for 3 doses. Max. total weekly dose 20mg. Acute lymphoblastic leukaemia: Low-dose: individual doses under 100 mg/m2; moderate- dose: individual doses between 100 mg/m2 and 1g/M 2; |
| Drug Interactions | |
| Pregnancy | Methotrexate may cause fetal death and/or congenital abnormalities. |
| Breast Feeding | Methotrexate is distributed in breastmilk. Breastfeeding is not recommended duri More ... |
| Active Ingredient | MITOMYCIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Upper gastro-intestinal and breast cancers and by bladder instillation for superficial bladder tumours. |
| Caution | Delayed bone-marrow toxicity , nausea, vomiting and anorexia, stomatitis, leukopenia, thrombocytopenia,alopecia. |
| Dose Range | According to disease and patient particulars. |
| Drug Interactions | |
| Pregnancy | Mitomycin can cause fetal harm in humans. Animal studies have shown delayed feta More ... |
| Breast Feeding | Mitomycin is distributed into breastmilk. Breastfeeding is not recommended durin More ... |
| Active Ingredient | NILOTINIB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OCRELIZUMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OXALIPLATIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Adminsiter with fluorouracil and folinic acid in the treatment of metastatic colorectal cancer and in the adjuvant treatment of stage III colon cancer. |
| Caution | As for cisplatin. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Oxaliplatin is not recommended during pregnancy.Women of child-bearing age shoul More ... |
| Breast Feeding | Breastfeeding is not recommended during therapy. |
| Active Ingredient | PACLITAXEL |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Primary treatment of advanced ovarian cancer with cisplatin or carbopatin, node-positive breast cancer. |
| Caution | Arrhythmia; arthralgia; febrile neutropenia; gastro-intestinal disorders; myalgia; peripheral neuropathy ; sensory neuropathy ; tachycardia. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PEGFILGRASTIM |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PEMBROLIZUMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RANIBIZUMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RITUXIMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia. |
| Caution | All patients should be screened for hepatitis B virus infection before starting rituximab; it should not be used in patients with active infection. Cytokine release syndrome (fever, chills, a More ... |
| Dose Range | 50 mg/hour, increased in increments of 50 mg/hour every 30 minutes to a maximum of 400 mg/hour, if well tolerated. Subsequent doses may be begun at a rate of 100 mg/hour, increased in increments of 100 mg/hour every 30 minutes to a maximum of 400 mg/hou |
| Drug Interactions | |
| Pregnancy | Avoid unless potential benefit to mother outweighs risk of B-lymphocyte depletio More ... |
| Breast Feeding | Avoid breast-feeding during and for 12 months after treatment. |
| Active Ingredient | SUNITINIB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TAMOXIFEN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Adjuvant endocrine therapy of node-positive breast cancer. |
| Caution |
Hot flashes, vaginal bleeding, pruritis vulvae, tumor flare, rarely fluid retention, cataracts, retinopathy , visual disturbances, venous thrombosis. |
| Dose Range | 20mg daily as a single or in 2 divided doses. Max. 40mg daily . |
| Drug Interactions | |
| Pregnancy | Tamoxifen is contraindicated in pregnancy as it may cause fetal harm. |
| Breast Feeding | Tamoxifen suppresses lactation. Liscensed product information recommends that it More ... |